Abiopharma

🔍 BERGER FRANKLIN M (Executive)

Company: Kezar Life Sciences, Inc. (KZR)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Sold 89,069 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: U | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 3,500 shares of Stock Option (right to buy) at $26.4 per share (Derivative)
  Date: 2026-05-11 | Code: D | Expires: 2033-06-14 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3
• Sold 5,000 shares of Stock Option (right to buy) at $6.7 per share (Derivative)
  Date: 2026-05-11 | Code: D | Expires: 2034-06-19 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4
• Sold 5,000 shares of Stock Option (right to buy) at $4.46 per share (Derivative)
  Date: 2026-05-11 | Code: D | Expires: 2035-06-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4
• Sold 2,600 shares of Stock Option (right to buy) at $22.8 per share (Derivative)
  Date: 2026-05-11 | Code: D | Expires: 2031-06-27 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3
• Sold 2,600 shares of Stock Option (right to buy) at $22.8 per share (Derivative)
  Date: 2026-05-11 | Code: D | Expires: 2032-06-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement")
• F2: (continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").
• F3: Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.
• F4: Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.